Biogen
NEWS
Using a calculation, ICER believes the Novartis gene therapy for Spinal Muscular Atrophy will be more cost effective than Biogen’s Spinraza.
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients.
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
JOBS
IN THE PRESS